Physician profile
Sunil Kumar Reddy
NPI 1952368433
$22,025.88
in general payments reported to CMS, 2019-2025
76 companies · $3,993 in 2025
The $3,993 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,056 · 2020: $3,101 · 2021: $3,523 · 2022: $3,020 · 2023: $2,563 · 2024: $2,771 · 2025: $3,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,304 · Consulting Fee: $23.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,303.57 |
| Consulting Fee | $23.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,212.29 | 2019-2025 | |
| Allergan, INC. | $1,418.25 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,366.15 | 2019-2024 | |
| Celgene Corporation | $1,335.18 | 2020-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $1,211.14 | 2019-2025 | Austedo Xr, Ajovy |
| Genzyme Corporation | $1,038.65 | 2019-2025 | |
| Ucb, INC. | $1,009.53 | 2019-2025 | Rystiggo, Zilbrysq |
| Amgen INC. | $991.48 | 2019-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $871.11 | 2020-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Biogen, INC. | $848.25 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Argenx US, INC. | $572.02 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $550.45 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Takeda Pharmaceuticals U.S.A., INC. | $508.59 | 2021-2025 | Hyqvia |
| Lundbeck LLC | $470.43 | 2020-2025 | Vyepti, Rexulti |
| Pfizer INC. | $466.17 | 2023-2025 |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.